
Asviia 3750 IU Injection
Salt Composition: Pegaspargase Injection
Expiry Date: 01/2028
Inclusive of all taxes
1 vial(s) of 5ml
About The Product
blood cancer
Description
Asviia 3750 IU Injection is a chemotherapy injection that shares some characteristics with targeted therapy. Doctor prescribed this medication as a first line therapy for treatment of acute lymphoblastic leukemia (ALL) and other blood cancers.
The medicine works by specifically targeting cancer cells and interfering with their growth and survival rate of tumor. Its active ingredient is Pegaspargase Injection belongs to the class of enzyme anti-cancer agents.
Strict medical supervision is needed while the medication is taken.
Uses
Acute lymphoblastic leukemia (ALL)
Common side effects
- Asviia 3750 IU Injection is an anti-cancer medication.
- It shows various side effects like other medications have.
- Consult the doctor if the symptoms persist: ● Diarrhea ● Fatigue ● Loss of appetite ● Headache ● Fever or chills ● Muscle or joint pain ● Anaphylaxis (severe allergic reaction) ● Thrombosis (blood clots) ● Hemorrhage (bleeding) ● Fever or chills ● Muscle or joint pain ● Rash or itching ● Swelling or redness at the injection site
How to use
- Asviia 3750 IU Injection should be taken with or without food at the fixed time everyday.
- The injection is typically administered under the supervision of a healthcare expert.
- Do not miss or stop the dose without consulting the doctor, as consistent treatment is crucial for its effectiveness.
How it works
Asviia Injection contains an active drug called pegaspargase, an enzyme that breaks down asparagine. Cancer cells particularly leukemia and lymphoma cells cannot produce asparagine on their own.
So the medicine deprives them of these essential nutrients thereby stopping their growth of cancer cells in the body.
Safety advice
FAQs
Asviia 3750 IU Injection treats blood cancer by blocking the.
Take a prescription at once before using the medication to ensure safe and effectiveness of the treatment.
Reference
• Guru, F. R., Akhter, R., Bashir, S., Nisar, S.
A., Mir, M. H., Zahir, Z., ... & Ara, U.
(2024). Efficacy and Safety Profile of Biosimilar Polyethylene Glycol (PEG)-Asparaginase (Asviia) in Patients With Acute Leukemia: A Retrospective Study From Kashmir.
Cureus, 16(11). • Heo, Y. A., Syed, Y.
Y., & Keam, S. J.
(2019). Pegaspargase: a review in acute lymphoblastic leukaemia.
Drugs, 79(7), 767-777. • Graham, M. L.
(2003). Pegaspargase: a review of clinical studies.
Advanced drug delivery reviews, 55(10), 1293-1302. • Ettinger, A. R.
(1995). Pegaspargase (oncaspar).
Journal of Pediatric Oncology Nursing, 12(1), 46-48. • Holle, L. M.
(1997). Pegaspargase: an alternative?.
Annals of Pharmacotherapy, 31(5), 616-624.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
